Dermata Therapeutics, Inc. – NASDAQ:DRMA
Dermata Therapeutics stock price today
Dermata Therapeutics stock price monthly change
Dermata Therapeutics stock price quarterly change
Dermata Therapeutics stock price yearly change
Dermata Therapeutics key metrics
Market Cap | 2.20M |
Enterprise value | N/A |
P/E | -0.1 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.15 |
PEG ratio | N/A |
EPS | -8.77 |
Revenue | N/A |
EBITDA | -8.96M |
Income | -8.68M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDermata Therapeutics stock price history
Dermata Therapeutics stock forecast
Dermata Therapeutics financial statements
| Jun 2023 | 0 | -1.70M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.71M | |
| Dec 2023 | 0 | -2.13M | |
| Mar 2024 | 0 | -3.13M |
| 2025 | 0 | -15.58M | |
|---|---|---|---|
| 2026 | 15M | -16.06M | -107.07% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.63 | -0.54 |
|---|---|---|
| 2024-02-07 | -0.78 | -0.21 |
| Jun 2023 | 8712881 | 682.86K | 7.84% |
|---|---|---|---|
| Sep 2023 | 7323383 | 916.81K | 12.52% |
| Dec 2023 | 7978634 | 1.62M | 20.35% |
| Mar 2024 | 5179756 | 1.37M | 26.48% |
| Jun 2023 | -1.84M | 0 | 1.51M |
|---|---|---|---|
| Sep 2023 | -1.77M | 0 | -35.41K |
| Dec 2023 | -1.14M | 0 | 1.95M |
| Mar 2024 | -2.70M | 0 | 0 |
Dermata Therapeutics alternative data
| Aug 2023 | 8 |
|---|---|
| Sep 2023 | 8 |
| Oct 2023 | 8 |
| Nov 2023 | 8 |
| Dec 2023 | 8 |
| Jan 2024 | 8 |
| Feb 2024 | 8 |
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Dermata Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 331428 | 0 |
| Nov 2021 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PROEHL GERALD T director, 10 perc.. | Common Stock | 20,000 | $2.4 | $48,000 | ||
Purchase | PROEHL GERALD T | Common Stock | 142,857 | N/A | N/A | ||
Purchase | PROEHL GERALD T | Warrant to Purchase Common Stock | 142,857 | N/A | N/A | ||
Purchase | HALE DAVID F | Common Stock | 35,714 | N/A | N/A | ||
Purchase | PROEHL GERALD T | Common Stock | 10,000 | $4.96 | $49,630 |
| Insider | Compensation |
|---|---|
Dr. Christopher J. Nardo M.P.H., Ph.D. (1966) Senior Vice President of Devel. | $270,000 |
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. (1954) Senior Vice President of Regulatory Affairs & Quality Assurance | $27,040 |
| Mr. Gerald T. Proehl (1959) Founder, Pres, Chief Executive Officer & Chairman | $27,040 |
-
What's the price of Dermata Therapeutics stock today?
One share of Dermata Therapeutics stock can currently be purchased for approximately $5.38.
-
When is Dermata Therapeutics's next earnings date?
Unfortunately, Dermata Therapeutics's (DRMA) next earnings date is currently unknown.
-
Does Dermata Therapeutics pay dividends?
No, Dermata Therapeutics does not pay dividends.
-
How much money does Dermata Therapeutics make?
Dermata Therapeutics has a market capitalization of 2.20M. Dermata Therapeutics made a loss 7.79M US dollars in net income (profit) last year or -$0.21 on an earnings per share basis.
-
What is Dermata Therapeutics's stock symbol?
Dermata Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DRMA".
-
What is Dermata Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Dermata Therapeutics?
Shares of Dermata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Dermata Therapeutics's key executives?
Dermata Therapeutics's management team includes the following people:
- Dr. Christopher J. Nardo M.P.H., Ph.D. Senior Vice President of Devel.(age: 59, pay: $270,000)
- Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance(age: 71, pay: $27,040)
- Mr. Gerald T. Proehl Founder, Pres, Chief Executive Officer & Chairman(age: 66, pay: $27,040)
-
Is Dermata Therapeutics founder-led company?
Yes, Dermata Therapeutics is a company led by its founder Mr. Gerald T. Proehl.
-
How many employees does Dermata Therapeutics have?
As Jul 2024, Dermata Therapeutics employs 8 workers.
-
When Dermata Therapeutics went public?
Dermata Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 13 Aug 2021.
-
What is Dermata Therapeutics's official website?
The official website for Dermata Therapeutics is dermatarx.com.
-
Where are Dermata Therapeutics's headquarters?
Dermata Therapeutics is headquartered at 3525 Del Mar Heights Road, San Diego, CA.
-
How can i contact Dermata Therapeutics?
Dermata Therapeutics's mailing address is 3525 Del Mar Heights Road, San Diego, CA and company can be reached via phone at 858 800 2543.
Dermata Therapeutics company profile:
Dermata Therapeutics, Inc.
dermatarx.comNASDAQ
8
Biotechnology
Healthcare
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
San Diego, CA 92130
CIK: 0001853816
ISIN: US2498453065
CUSIP: 249845108
